The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Oka, Toshiki; Hatano, Koji; Okuda, Yohei; Yamamoto, Akinaru; Uemura, Toshihiro; Yamamichi, Gaku; Tomiyama, Eisuke; Ishizuya, Yu; Yamamoto, Yoshiyuki; Kato, Taigo; Kawashima, Atsunari; Fujita, Kazutoshi; Nonomura, Norio

doi:https://doi.org/10.1007/s10147-022-02288-5

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

Oka, Toshiki; Hatano, Koji; Okuda, Yohei et al.

International Journal of Clinical Oncology, 2022, 28, 427-435

アクセス数:1,939件（2025-08-14 21:25 集計）

固定URL: https://hdl.handle.net/11094/90045

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
IntJClinOncol_Oka	pdf	なし	593 KB	91	2023.12.29
Supplementary Table 1_RV1_2022.12.08	pdf	なし	85.8 KB	42	2023.12.29	Supplementary Table 1.

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
著者	NRID 1000060964385 1000060964385 著者名 Oka, Toshiki
	NRID 1000060762234 1000060762234 researchmap permalink koji_hatano koji_hatano Scopus Author ID 14627167600 14627167600 著者名 Hatano, Koji
	NRID 1000010964372 1000010964372 著者名 Okuda, Yohei
	NRID 1000050909653 1000050909653 著者名 Yamamoto, Akinaru
	NRID 1000060905941 1000060905941 著者名 Uemura, Toshihiro
	NRID 1000040882262 1000040882262 著者名 Yamamichi, Gaku
	NRID 1000040845244 1000040845244 著者名 Tomiyama, Eisuke
	NRID 1000000783854 1000000783854 researchmap permalink okiishi okiishi 著者名 Ishizuya, Yu
	NRID 1000090759557 1000090759557 researchmap permalink yoshi229 yoshi229 ORCID 0000-0002-1271-3521 0000-0002-1271-3521 著者名 Yamamoto, Yoshiyuki
	NRID 1000070648021 1000070648021 researchmap permalink taigokato taigokato Scopus Author ID 55414697500 55414697500 ORCID 0000-0002-8681-1407 0000-0002-8681-1407 著者名 Kato, Taigo
	NRID 1000050746568 1000050746568 researchmap permalink akawashima akawashima Scopus Author ID 9846139400 9846139400 著者名 Kawashima, Atsunari
	NRID 1000050636181 1000050636181 著者名 Fujita, Kazutoshi
	NRID 1000030263263 1000030263263 researchmap permalink read0185096 read0185096 Scopus Author ID 7005880662 7005880662 著者名 Nonomura, Norio
キーワード等	Androgen receptor antagonist
	Castration-resistant prostate cancer
	Enzalutamide
	Lymph node metastasis
	Progression-free survival
	Prostate-specific antigen
内容	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10147-022-02288-5.
抄録	Background: Enzalutamide is effective against castration-resistant prostate cancer (CRPC). However, it is unclear which patients would benefit more from enzalutamide treatment. Here, we analyzed patients who received enzalutamide as first-line therapy for CRPC and evaluated the factors that predict treatment response and prognosis. Methods: We retrospectively analyzed 101 patients treated with enzalutamide for CRPC at our institution. As primary endpoints we regarded the prostate-specific antigen (PSA) response rate and PSA–progression-free survival (PSA–PFS) from the start of enzalutamide treatment. Laboratory and imaging data were analyzed to predict treatment efficacy. Results: PSA reductions of ≥ 50% and ≥ 90% were observed in 78 (77%) and 47 (47%) patients, respectively, compared with the baseline. During the follow-up period, 67 (66%) patients showed PSA progression, with a median PSA–PFS of 11 months. Moreover, 31 patients (31%) died, with a median overall survival of 64 months. On multivariate analysis, lymph node metastases at the start of enzalutamide treatment [odds ratio (OR) 0.0575, 95% confidence interval (CI) 0.0105–0.316, p = 0.0010] and time to CRPC (OR 0.177, 95% CI 0.0428–0.731, p = 0.0167] were associated with ≥ 90% PSA response. Lymph node metastases (hazard ratio [HR] 3.00, 95% CI 1.48–6.09, p = 0.0023) and time to CRPC (HR 1.84, 95% CI 1.02–3.30, p = 0.0419) were also predictors of PSA–PFS on a multivariate model. Conclusions: Time to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA–PFS.
出版者	Springer
収録物名	International Journal of Clinical Oncology
巻(号)	28
ページ	427-435
刊行年月	2022-12-29
言語	英語
ハンドルURL	https://hdl.handle.net/11094/90045
PISSN	13419625
eISSN	14377772
NCID	AA11086579
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1007/s10147-022-02288-5
アクセス権	open access
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	International Journal of Clinical Oncology. 2022, 28, p. 427-435
DC.title	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
DC.creator	Oka, Toshiki
	Hatano, Koji
	Okuda, Yohei
	Yamamoto, Akinaru
	Uemura, Toshihiro
	Yamamichi, Gaku
	Tomiyama, Eisuke
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Kato, Taigo
	Kawashima, Atsunari
	Fujita, Kazutoshi
	Nonomura, Norio
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2022-12-29
DC.identifier	https://doi.org/10.1007/s10147-022-02288-5
DC.subject	Androgen receptor antagonist
	Castration-resistant prostate cancer
	Enzalutamide
	Lymph node metastasis
	Progression-free survival
	Prostate-specific antigen
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10147-022-02288-5.
DCTERMS.abstract	Background: Enzalutamide is effective against castration-resistant prostate cancer (CRPC). However, it is unclear which patients would benefit more from enzalutamide treatment. Here, we analyzed patients who received enzalutamide as first-line therapy for CRPC and evaluated the factors that predict treatment response and prognosis. Methods: We retrospectively analyzed 101 patients treated with enzalutamide for CRPC at our institution. As primary endpoints we regarded the prostate-specific antigen (PSA) response rate and PSA–progression-free survival (PSA–PFS) from the start of enzalutamide treatment. Laboratory and imaging data were analyzed to predict treatment efficacy. Results: PSA reductions of ≥ 50% and ≥ 90% were observed in 78 (77%) and 47 (47%) patients, respectively, compared with the baseline. During the follow-up period, 67 (66%) patients showed PSA progression, with a median PSA–PFS of 11 months. Moreover, 31 patients (31%) died, with a median overall survival of 64 months. On multivariate analysis, lymph node metastases at the start of enzalutamide treatment [odds ratio (OR) 0.0575, 95% confidence interval (CI) 0.0105–0.316, p = 0.0010] and time to CRPC (OR 0.177, 95% CI 0.0428–0.731, p = 0.0167] were associated with ≥ 90% PSA response. Lymph node metastases (hazard ratio [HR] 3.00, 95% CI 1.48–6.09, p = 0.0023) and time to CRPC (HR 1.84, 95% CI 1.02–3.30, p = 0.0419) were also predictors of PSA–PFS on a multivariate model. Conclusions: Time to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA–PFS.
DC.format	90045
citation_title	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
citation_author	Oka, Toshiki
	Hatano, Koji
	Okuda, Yohei
	Yamamoto, Akinaru
	Uemura, Toshihiro
	Yamamichi, Gaku
	Tomiyama, Eisuke
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Kato, Taigo
	Kawashima, Atsunari
	Fujita, Kazutoshi
	Nonomura, Norio
citation_publisher	Springer
citation_language	英語
citation_date	2022-12-29
citation_journal_title	International Journal of Clinical Oncology
citation_volume	28
citation_firstpage	427
citation_lastpage	435
citation_doi	https://doi.org/10.1007/s10147-022-02288-5
citation_public_url	https://hdl.handle.net/11094/90045

The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer

閲覧可能ファイル

論文情報

論文詳細を表示